New data suggest that incidence and prevalence of inflammatory bowel diseases [IBD] are
still increasing worldwide, and approximately 0.2% of the European population suffer from …

The cost of caring for patients with inflammatory bowel disease (IBD) continues to increase
worldwide. The cause is not only a steady increase in the prevalence of Crohn's disease …

Tumor Necrosis Factor Inhibitors for Inflammatory Bowel Disease | New England Journal of
Medicine Skip to main content The New England Journal of Medicine homepage Advanced …

(1) Aims: To assess the incidence of inflammatory bowel disease (IBD) in Spain, to describe
the main epidemiological and clinical characteristics at diagnosis and the evolution of the …

Background Knowledge of the cost of illness of inflammatory bowel disease (IBD) is
essential for health policy makers worldwide. Aim To assess the cost of illness of IBD from …

BACKGROUND Delays in advancing to biologic therapies are associated with adverse
outcomes in inflammatory bowel disease (IBD). Insurer-mandated prior authorizations have …

Treatment targets of inflammatory bowel diseases (IBD), ulcerative colitis (UC) and Crohn's
disease (CD) have evolved over the last decade. Goals of therapy consisting of symptom …

Background Therapeutic management of inflammatory bowel diseases (IBD) is rapidly
evolving, with an expanding armoury of biological drugs at our disposal. However, real …

Inflammatory bowel disease is characterized by significant interindividual heterogeneity.
With a wider selection of pharmacologic and nonpharmacologic interventions available and …

Background Inflammatory bowel disease (IBD) follows a heterogenous disease course and
predicting a patient's prognosis is challenging. There is a wide burden of illness in IBD and …